Evaluating Gemtuzumab in AML Treatment

This chapter critically examines the use of gemtuzumab for patients with acute myeloid leukemia (AML), highlighting biases in retrospective studies and concerns over patient selection. It discusses the risks associated with gemtuzumab, including severe toxicities and the implications for treatment logistics, while questioning its effectiveness compared to traditional chemotherapy. The conversation emphasizes the importance of evolving treatment approaches and integrating patient preferences in decision-making.